PNC Financial Services Group’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$540K Buy
1,854
+261
+16% +$86.4K ﹤0.01% 1774
2026
Q2
$533K Buy
1,593
+640
+67% +$203K ﹤0.01% 1742
2026
Q1
$307K Buy
953
+239
+33% +$73.9K ﹤0.01% 2027
2025
Q4
$210K Buy
714
+690
+2,875% +$128K ﹤0.01% 2276
2025
Q3
$1.27K Hold
24
– – ﹤0.01% 4627
2025
Q2
$1.01K Buy
24
+19
+380% +$724 ﹤0.01% 4563
2025
Q1
$189 Buy
5
+3
+150% +$187 ﹤0.01% 4783
2024
Q4
$154 Buy
+2
New +$145 ﹤0.01% 4674

Other funds holding PRAX

PNC Financial Services Group's PRAX Position: Q3 2026 in Review

PNC Financial Services Group increased its Praxis Precision Medicines (PRAX) stake by 16% in Q3 2026, buying an estimated $86.4K and bringing the position to 1,854 shares worth $540K. The position accounts for ﹤0.01% of the portfolio, ranked #1774.

PNC Financial Services Group first reported a position in PRAX in Q4 2024 and has held it in 8 quarters since. 339 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

  • PNC Financial Services Group held 1,854 shares of Praxis Precision Medicines worth $540K as of Q3 2026.
  • PNC Financial Services Group bought 261 Praxis Precision Medicines shares in Q3 2026, an estimated $86.4K.
  • Praxis Precision Medicines made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #1774 holding.
  • PNC Financial Services Group first reported a position in Praxis Precision Medicines in Q4 2024 and has held it in 8 quarters since.
  • 339 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.